Takeda Pharmaceuticals Licenses Recombineering Technology from Gene Bridges
News Oct 08, 2008
Gene Bridges GmbH, the recombineering company, has announced that Takeda Pharmaceutical Company Limited of Osaka, Japan has completed a commercial license agreement for the use of the Red/ET recombination technology from Gene Bridges.
The Red/ET recombination technology, patented in Japan under the title "Novel DNA Cloning Method“, is a valued method for generating targeting vectors or modifying E. coli chromosomes.
Gary Stevens, CEO of Gene Bridges GmbH, commented: ‘We are very pleased to add such a major player as Takeda to the list of companies using the technology in Japan. Their decision shows that Red/ET recombineering is the technology of choice in DNA engineering’.
Gene Bridges is represented in Japan by the distribution partner Funakoshi and will be exhibiting at BIO Japan 2008 World Business Forum at Yokohama, Japan on October 15-17.
Red/ET is a revolutionary method for DNA engineering. Recombineering with Red/ET allows cloning, subcloning, and modification of DNA at any chosen position. It permits precise engineering of DNA molecules of any size, including very large ones such as BACs or the E.coli chromosome.
Mechanism Controlling Multiple Sclerosis Risk IdentifiedNews
Researchers at Karolinska Institutet have now discovered a new mechanism of a major risk gene for multiple sclerosis (MS) that triggers disease through so-called epigenetic regulation. They also found a protective genetic variant that reduces the risk for MS through the same mechanism.
Synthetic DNA Shuffling Enzyme Outpaces Natural CounterpartNews
A new synthetic enzyme, crafted from DNA rather than protein, flips lipid molecules within the cell membrane, triggering a signal pathway that could be harnessed to induce cell death in cancer cells. Researchers say their lipid-scrambling DNA enzyme is the first in its class to outperform naturally occurring enzymes – and does so by three orders of magnitudeREAD MORE
Antarctic Worm and Machine Learning Help Identify Cerebral Palsy EarlierNews
A research team has released a study in the peer-reviewed journal BMC Bioinformatics showing that DNA methylation patterns in circulating blood cells can be used to help identify spastic cerebral palsy (CP) patients. The technique which makes use of machine learning, data science and even analysis of Antarctic worms, raises hopes for earlier targeted CP therapies.